Abstract: The invention relates to nucleotide sequences encoding human interleukin-3 (hIL-3) as well as recombinant DNAs, expression cassettes, transformed host cells, and recombinant expression methods comprising such sequences. Additionally, the invention describes proteins having hIL-3 activity, as purified, recombinantly produced, or fusion protein forms of hIL-3, as well as methods of using such proteins to produce antibodies capable of immunospecific reaction with hIL-3.

Abstract: The invention provides novel developmentally-regulated hippocampal genes and polypeptides encoded by those genes. The invention also provides expression vectors, host cells, and antibodies. The invention also provides methods for diagnosing, treating or preventing diseases associated with hippocampus.

Abstract: Mammalian genes and proteins, designated cytokine synthesis inhibitory factors (CSIF's, now known as Interleukin-10 (IL-10)), are provided which are capable of inhibiting the synthesis of cytokines associated with delayed type hypersensitivity responses, and which, together with antagonists, are useful in treating diseases associated with cytokine imbalances, such as leishmaniasis and other parasitic infections, and certain immune disorders including MHC associated autoimmune diseases caused by excessive production of interferon-&ggr;.

Abstract: A polypeptide which has a molecular weight of 18,500±3,000 daltons on SDS-PAGE and a pI of 4.9±1.0 on chromatofocusing. The polypeptide strongly induces the IFN-&ggr; production by immunocompetent cells with only a small amount, and does not cause serious side effects even when administered to human in a relatively-high dose. It can be used to treat and/or prevent malignant tumors, viral diseases, bacterial infectious diseases, and immune diseases.

Abstract: A nucleic acid which can be used to express a polypeptide with interleukin-16 activity in a prokaryotic or eukaryotic host cell, wherein in the region coding for the said polypeptide the said nucleic acid a)corresponds to the DNA sequence of nucleotides 54-1175 from SEQ ID NO:1 or to its complementary strand, b) hybridizes with the DNA of nucleotide sequence 54-785 from SEQ ID NO:1 under stringent conditions, c) hybridizes with the DNA of nucleotide sequence 786-1175 from SEQ ID NO:1 under stringent conditions and at the 5′ end begins with nucleotides 756-785 from SEQ ID NO:1 or a part thereof which codes for part of the sequence of amino acids 235-244 from SEQ ID NO:1 or d) it is a nucleic acid sequence which would hybridize under stringent conditions with the nucleic acid sequences defined by a) or b) without the degeneracy of the genetic code, codes for proteins with improved interleukin-16 activity.

Abstract: Stably-transformed human cell lines containing a reporter gene operatively linked to an IL-4-responsive element are provided. In some embodiments a human Fc&egr;RII IL-4-responsive element is used. In other embodiments a human germline &egr; transcript promoter is used as the responsive element. Also provided are methods for using such transformed cell lines to screen for agonists and/or antagonists of human interleukin-4.